These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 27208980

  • 1. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
    Samama CM, Rosencher N, Kleine E, Feuring M, Brueckmann M, Clemens A, Gullberg J, Frostick SP.
    Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S, PROPICE Study Group.
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR.
    JAMA Intern Med; 2020 Mar 01; 180(3):376-384. PubMed ID: 32011647
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, Simon TA, Sutton A.
    Clin Appl Thromb Hemost; 2012 Nov 01; 18(6):611-27. PubMed ID: 22387582
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
    Eriksson BI, Friedman RJ.
    Clin Appl Thromb Hemost; 2009 Nov 01; 15 Suppl 1():25S-31S. PubMed ID: 19648146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.
    Mayer A, Schuster P, Fink B.
    Arch Orthop Trauma Surg; 2017 Jun 01; 137(6):797-803. PubMed ID: 28439702
    [Abstract] [Full Text] [Related]

  • 20. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
    Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM.
    Pharmacoepidemiol Drug Saf; 2011 Sep 01; 20(9):972-8. PubMed ID: 21748826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.